Dec 19 (Reuters) - Amicus Therapeutics Inc (FOLD.O) said it had positive results from Phase II clinical trials of Amigal for Fabry disease.
Based on the results, Amicus said it and its partner, Shire Human Genetic Therapies, plan to meet with U.S. and European regulatory authorities to discuss the design of a Phase III trial.
Shire Human Genetics Therapies is a unit of Shire Plc. (Reporting by Sharangdhar Limaye in Bangalore)
KANEOHE, Hawaii (Reuters) - President Barack Obama on Tuesday blamed "human and systemic failures" for allowing a botched Christmas Day attack aboard a Detroit-bound airliner and a U.S. official said the incident was linked to al Qaeda. | Video
The "Arrowhead" gives Asia's largest -- and long derided -- bourse a viable electronic trading platform, it hopes. Full Article
Shrinking financial sector? Paltry investment returns? Welcome to the the next decade. Don't worry, there's some good news, too. Commentary
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
